Open AccessRadiotherapy for gastric mucosa-associated lymphoid tissue lymphoma
Author(s) -
L. Quéro,
M. Labidi,
Marc A. Bollet,
Côme Bommier,
S. Guillerm,
Christophe Hennequin,
Catherine Thiéblemont
Publication year - 2021
Publication title -
world journal of gastrointestinal oncology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v13.i10.1453
Subject(s) - medicine , helicobacter pylori , lymphoma , malt lymphoma , radiation therapy , lymphatic system , gastric mucosa , gastric lymphoma , gastroenterology , mucosa associated lymphoid tissue , stomach , adenocarcinoma , pathology , cancer
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease which is often associated with Helicobacter pylori ( H. pylori ) infection. First-line treatment of stage IE and IIE localized gastric MALT lymphoma is based on the eradication of H. pylori . The presence of H. pylori resistance factors such as translocation t (11;18), peri-gastric lymph node involvement and the degree of tumor infiltration of the gastric wall; or lack of response to antibiotic therapy are two main indications to treat with definitive radiotherapy (RT). RT is an effective treatment in localized gastric MALT lymphoma. A moderate dose of 30 Gy allows a high cure rate while being well tolerated. After treatment, regular gastric endoscopic follow-up is necessary to detect a potential occurrence of gastric adenocarcinoma.